New inhaler hope for COPD patients in early trial
NCT ID NCT07140328
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called HSK39004, given as an inhaler, in 50 adults with chronic obstructive pulmonary disease (COPD). Participants are randomly assigned to receive either the drug or a placebo for 4 weeks. The main goal is to see if the drug improves lung function compared to placebo. This is an early-stage trial to check both safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HSK39004 (an experimental drug inhaled as a dry powder or suspension)
- What this could lead to
- If successful, this could lead to a new inhaled treatment option for people with COPD to help improve their breathing and lung function.
- What could go wrong
- This is an early Phase 2 trial with only 50 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE LUNG DISEASE (COLD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangsu Provincial People's Hospital
RECRUITINGNanchang, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.